Faculty, Staff and Student Publications
Publication Date
2-7-2024
Journal
Molecular Therapy
Abstract
Multiple myeloma (MM) is a rarely curable malignancy of plasma cells. MM expresses B cell maturation antigen (BCMA). We developed a fully human anti-BCMA chimeric antigen receptor (CAR) with a heavy-chain-only antigen-recognition domain, a 4-1BB domain, and a CD3ζ domain. The CAR was designated FHVH33-CD8BBZ. We conducted the first-in-humans clinical trial of T cells expressing FHVH33-CD8BBZ (FHVH-T). Twenty-five patients with relapsed MM were treated. The stringent complete response rate (sCR) was 52%. Median progression-free survival (PFS) was 78 weeks. Of 24 evaluable patients, 6 (25%) had a maximum cytokine-release syndrome (CRS) grade of 3; no patients had CRS of greater than grade 3. Most anti-MM activity occurred within 2-4 weeks of FHVH-T infusion as shown by decreases in the rapidly changing MM markers serum free light chains, urine light chains, and bone marrow plasma cells. Blood CAR
Keywords
Humans, Multiple Myeloma, Receptors, Chimeric Antigen, T-Lymphocytes, Immunotherapy, Adoptive, Bone Marrow, CAR, CCR7, multiple myeloma therapy, RNA-seq, immunogenicity, T cell, immunotherapy, clinical trial
DOI
10.1016/j.ymthe.2023.12.018
PMID
38155568
PMCID
PMC10861980
PubMedCentral® Posted Date
12-28-2023
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes
Included in
Immunotherapy Commons, Medical Sciences Commons, Neoplasms Commons, Oncology Commons, Public Health Commons